Symbols

Symbols

MYGN

MYGN News

Newswire

12:39

Myriad Genetics Unveils Roadmap for Precise MRD Assay Commercialization in Breast, Colorectal, Renal, Ovarian, and Endometrial Cancers

08:52

Myriad Advances MRD Commercialization with New Study Data

08:37

Myriad Genetics reports Q4 rev. $207-209 mln, FY25 rev. $822-824 mln.

08:33

Myriad Genetics Reports Preliminary Q4, Full Year 2025 Results, Outlines FY26 Guidance

15:22

Myriad Genetics Stock Trades Up Amid Exclusive Agreement with Zydus Lifesciences

About MYGN

--

Sector--

Established Date--

Listing Date--

Exchange--

Full-time Employees--

Fiscal Year Ends--

Website

Security Type--

Office address

Business

Introduction